K
Kwang Hyub Han
Researcher at Yonsei University
Publications - 694
Citations - 36674
Kwang Hyub Han is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis B virus. The author has an hindex of 80, co-authored 692 publications receiving 30974 citations. Previous affiliations of Kwang Hyub Han include University Health System.
Papers
More filters
Journal ArticleDOI
M1907 Efficacy of Entecavir in Nucleoside-NaïVe Patients with Mildly Elevated ALT
Stuart C. Gordon,Steven-Huy B. Han,Ting-Tsung Chang,Ching-Lung Lai,Kwang Hyub Han,You Chen Chao,Chee-Kiat Tan,William Sievert,Tawesak Tanwandee,Boon-Leong Neo +9 more
Journal ArticleDOI
Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study.
Mi Young Jeon,Beom Kyung Kim,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Kwang Hyub Han,Jeong Hoon Lee,Su Jong Yu,Yoon Jun Kim,Jung Hwan Yoon,Eun Ju Cho,Seung Up Kim +11 more
TL;DR: A new pHAP score optimized for patients treated with TACE due to recurrent HCC after resection showed acceptable accuracy and was externally validated.
Journal ArticleDOI
HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study
Wan-Lung Chuang,Jidong Jia,Hung Chan,Kwang Hyub Han,Tawesak Tanwandee,Deming Tan,X.-P. Chen,E.J. Gane,Teerha Piratvisuth,Lei Chen,Qing Xie,Joseph J.Y. Sung,Diethelm Messinger,Cynthia Wat,Georgios Bakalos,Yun-Fan Liaw +15 more
Journal Article
PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM
Samuel S. Lee,Yves Horsmans,Stuart K. Roberts,Hanna Berak,Geoffrey Dusheiko,Hugh Harley,Edward Gane,Petr Husa,Kwang Hyub Han,Stephanos J. Hadziyannis,E. Jenny Heathcote,Diethelm Messinger,Andreas Tietz,Peter Ferenci +13 more
Journal ArticleDOI
Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Riccardo Lencioni,Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Ann-Lii Cheng,Fabio Piscaglia,Guohong Han,Masafumi Ikeda,Krzysztof Simon,Dmitry Komov,Xuenong OuYang,T.R. Jeffry Evans,Max W. Sung,Terri A. Binder,Andrew Damon,Silvija Kraljevic,Min Ren,Baek-Yeol Ryoo +19 more
TL;DR: LEN showed treatment effect on OS by statistical demonstration of noninferiority to SOR in a phase 3 study in pts with uHCC, with significant improvement in median PFS, TTP, and ORR by mRECIST.